6:29 am - Sunday October 22, 2017

Chiltern Acquires Japanese Clinical Research Organization Integrated Development Associates Co. Ltd.

Comments Off on Chiltern Acquires Japanese Clinical Research Organization Integrated Development Associates Co. Ltd.
single-thumb.jpg
Business Wire India

Chiltern, a leading global contract research organization, has acquired Integrated Development Associates Co. Ltd. (IDA), a CRO specializing in integrating Japan and Asia into global drug development.

 

With staff based in Japan, Korea and Southeast Asia, IDA has extensive expertise in establishing regulatory and development pathways for Japan and implementing Pan Asian clinical trials to achieve both Japanese and global regulatory objectives. IDA’s experience in a broad range of therapeutic areas and its local knowledge and relationships will allow Chiltern to offer optimal approaches for integrating Japan and Asia into global drug development. In addition, the acquisition opens opportunities for Japanese companies to enter a wider market by relying on Chiltern’s global expertise and connections.

 

“The acquisition of IDA is driven by our commitment to establish a substantial presence in all major global markets and support our clients with clinical development capabilities worldwide,” said Jim Esinhart, Ph.D., Chiltern CEO. “Japan and Southeast Asia are among the world’s largest and fastest-growing pharmaceutical markets. IDA will enable us to grow in the APAC region through well-established relationships and local expertise and knowledge.”

 

IDA will do business as a wholly owned subsidiary of Chiltern and be renamed IDA, a Chiltern Company. As a part of this agreement, IDA’s founder and CEO, John Winebarger, will continue to lead IDA. Winebarger has more than 30 years’ experience working in Japan and will join Chiltern’s leadership team.

 

To learn more about Chiltern’s global clinical development services, visit Chiltern.com.

 

About Chiltern
Chiltern, a global contract research organization, is a leading provider of clinical services and solutions in a variety of therapeutic areas with engagement models for biopharmaceutical and medical device industries. Chiltern’s team of more than 4,300, located across 47 countries, provides comprehensive Clinical Development, Medical & Scientific Affairs, Data & Analysis, Pharmacovigilance and Strategic Regulatory services using a collaborative approach for more efficient clinical trials. Visit Chiltern.com to learn more about how Chiltern is Designed Around You®.

 

 

 

 

Don't miss the stories followThe CEO Magazine and let's be smart!
Loading...
0/5 - 0
You need login to vote.
prev-next.jpg

Synacor’s Zimbra Platform Receives Top Marks in Radicati’s 2017 Report on Email Platforms

KhelPlay’s Poker Tournaments and Events a Big Hit in Indian Metro Cities

Related posts
Comments are closed